Gyros AB Continues Expansion into US Contract Research Organizations
Alan Breau, Vice President for Bioanalytical/Analytical Services said, “Data from immunoassays underpin many critical decisions within complex project workflows. Our goal as a CRO is to deliver high quality results as rapidly and cost-effectively as possible to our clients in the biopharmaceutical industry. The automated, precise nanoliter-scale immunoassay platform from Gyros enables us to quickly develop project specific biomarker, pharmacokinetic (PK) and immunogenicity assays and to easily transfer the running of established assays thereby freeing staff for other tasks. The ability to work with such small volumes ensures that we maximize the number of assays that can be performed on samples that are often in limited supply. We believe that this investment will significantly impact the cost-efficiency as well as the turnaround time of our preclinical and clinical studies.”
Commenting on the announcement, Erik Walldén, CEO at Gyros, added: “With major biopharmaceutical companies using our platform to increase workflow efficiency, it is extremely pleasing that a growing number of their service providers are following suit. We have seen several examples of highly successful collaborations where both parties have benefited from increased productivity overall and noted the ease with which assays can be transferred between sites. This purchase by a well-established company such as MPI Research reflects the growing acceptance of our nanoliter-scale immunoassay platform within the industry.
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.
Enquiries:
Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7811 996 942
Skype: lorna.cuddon
Email: lorna.cuddon@zymecommunications.com
www.zymecommunications.com
About MPI research (www.mpiresearch.com)
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring relationships characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world.
Gyros at MPI Research Enquiries:
Mark Cameron
Associate Director for Biomarkers and Assay Development
Tel: +1-269-668-3336 ext 1816
Email: mark.cameron@mpiresearch.com
MPI Research Enquiries:
Ed Amat, Vice President of Global Sales
Tel: +1-269-668-3336 ext 3156
Email: ed.amat@mpiresearch.com